KR20240117556A - 유비퀴틴 특이적 프로테아제 1(usp1)의 소분자 억제제 및 이의 용도 - Google Patents

유비퀴틴 특이적 프로테아제 1(usp1)의 소분자 억제제 및 이의 용도 Download PDF

Info

Publication number
KR20240117556A
KR20240117556A KR1020247018882A KR20247018882A KR20240117556A KR 20240117556 A KR20240117556 A KR 20240117556A KR 1020247018882 A KR1020247018882 A KR 1020247018882A KR 20247018882 A KR20247018882 A KR 20247018882A KR 20240117556 A KR20240117556 A KR 20240117556A
Authority
KR
South Korea
Prior art keywords
optionally substituted
alkyl
heterocycloalkyl
cycloalkyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247018882A
Other languages
English (en)
Korean (ko)
Inventor
지엔핑 우
루오헝 친
진신 리우
Original Assignee
인실리코 메디신 아이피 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인실리코 메디신 아이피 리미티드 filed Critical 인실리코 메디신 아이피 리미티드
Publication of KR20240117556A publication Critical patent/KR20240117556A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020247018882A 2021-11-12 2022-11-11 유비퀴틴 특이적 프로테아제 1(usp1)의 소분자 억제제 및 이의 용도 Pending KR20240117556A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021130290 2021-11-12
CNPCT/CN2021/130290 2021-11-12
CN2022123827 2022-10-08
CNPCT/CN2022/123827 2022-10-08
PCT/CN2022/131293 WO2023083286A1 (en) 2021-11-12 2022-11-11 Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof

Publications (1)

Publication Number Publication Date
KR20240117556A true KR20240117556A (ko) 2024-08-01

Family

ID=86335131

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247018882A Pending KR20240117556A (ko) 2021-11-12 2022-11-11 유비퀴틴 특이적 프로테아제 1(usp1)의 소분자 억제제 및 이의 용도

Country Status (19)

Country Link
US (3) US20250026754A1 (https=)
EP (1) EP4430050A4 (https=)
JP (1) JP2024543477A (https=)
KR (1) KR20240117556A (https=)
CN (1) CN119053601A (https=)
AR (1) AR127646A1 (https=)
AU (1) AU2022386486A1 (https=)
CA (1) CA3235765A1 (https=)
CL (2) CL2024001397A1 (https=)
CO (1) CO2024006269A2 (https=)
CR (1) CR20240191A (https=)
DO (1) DOP2024000080A (https=)
GE (1) GEAP202416532A (https=)
IL (1) IL312642A (https=)
JO (1) JOP20240096A1 (https=)
MX (1) MX2024005755A (https=)
PE (1) PE20241307A1 (https=)
TW (1) TW202334142A (https=)
WO (1) WO2023083286A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312642A (en) 2021-11-12 2024-07-01 Insilico Medicine Ip Ltd Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
EP4605391A1 (en) * 2022-10-21 2025-08-27 Exelixis, Inc. 4,5,6,7-tetrahydro-1-pyrazolo[4,3-c]pyridine compounds and derivatives as usp1 inhibitors
WO2025010245A1 (en) 2023-07-06 2025-01-09 Exelixis, Inc. Fused pyrazole derivatives as usp1 inhibitors
TW202519226A (zh) 2023-11-08 2025-05-16 美商艾克塞里克斯公司 使用抑制ｐｋｍｙｔ１之化合物治療癌症之方法
WO2025102016A1 (en) 2023-11-10 2025-05-15 Vrise Therapeutics, Inc. Novel molecules as inhibitors of dna damage repair pathway
TW202539659A (zh) 2024-01-10 2025-10-16 美商維瑞斯治療股份有限公司 Ｄｎａ損傷修復途徑的新穎抑制劑
WO2025227060A1 (en) 2024-04-26 2025-10-30 Insilico Medicine Ip Limited Heterocyclic inhibitors of ubiquitin specific protease 1 (usp1) in combination with additional agents for use in the treatment of cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4337611A1 (de) 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
NZ511674A (en) * 1998-12-23 2003-11-28 Du Pont Pharm Co Nitrogen containing heterobicycles as factor Xa inhibitors
JP4166991B2 (ja) 2001-02-26 2008-10-15 田辺三菱製薬株式会社 ピリドピリミジンまたはナフチリジン誘導体
JP2004083587A (ja) 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
ITFR20030005U1 (it) 2003-03-17 2003-06-16 C D R Sistema di protezione solare (frangisole f1)
JP2010208945A (ja) 2007-06-01 2010-09-24 Mitsubishi Tanabe Pharma Corp 複素環化合物
JP5063815B2 (ja) 2008-11-25 2012-10-31 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 抗腫瘍および抗神経変性剤としての二環式ピラゾールおよびイソオキサゾール誘導体
MX2012004846A (es) 2009-10-29 2012-10-05 Genosco Inhibidores de cinasa.
RU2012131124A (ru) 2009-12-23 2014-01-27 Элан Фармасьютикалз, Инк. Птеридиноны как ингибиторы polo-подобных киназ
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
US9242981B2 (en) * 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
AU2011376721B2 (en) 2011-09-16 2017-06-08 Sanofi Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
EP2938610A2 (en) 2012-12-28 2015-11-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
CN104311555B (zh) 2014-09-19 2016-04-20 广东东阳光药业有限公司 吡唑并哌啶酮类化合物及其组合物及用途
EP3632915A1 (en) 2014-11-27 2020-04-08 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
CN108473495B (zh) 2015-11-20 2022-04-12 福马治疗有限公司 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
JP7014736B2 (ja) 2016-05-24 2022-02-01 ジェネンテック， インコーポレイテッド がんの処置のためのピラゾロピリジン誘導体
EA201992780A1 (ru) 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
US11413288B2 (en) 2017-11-01 2022-08-16 Dana-Farber Cancer Institute, Inc. Methods of treating cancers
US11485736B2 (en) * 2018-12-20 2022-11-01 KSQ Therapeutics, Inc. Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors
US20220073525A1 (en) * 2018-12-28 2022-03-10 Forma Therapeutics, Inc. Compositions for inhibiting ubiquitin specific protease 1
WO2021163530A1 (en) * 2020-02-14 2021-08-19 KSQ Therapeutics, Inc. Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors
EP4161494A4 (en) 2020-06-02 2024-07-17 KSQ Therapeutics, Inc. NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS
KR20230098186A (ko) 2020-10-30 2023-07-03 케이에스큐 세러퓨틱스 인코포레이티드 치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도
WO2022174031A1 (en) 2021-02-12 2022-08-18 Relay Therapeutics, Inc. Cdk inhibitors and methods of use thereof
EP4291559A1 (en) 2021-02-15 2023-12-20 Tango Therapeutics, Inc. Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer
WO2022197892A1 (en) 2021-03-17 2022-09-22 Tango Therapeutics, Inc. Purine derivatives as anticancer agents
WO2022199652A1 (en) 2021-03-24 2022-09-29 Impact Therapeutics (Shanghai) , Inc Five-membered heteroaryl-pyrimidine compounds as usp1 inhibitors and the use thereof
CA3214040A1 (en) 2021-04-07 2022-10-13 Forma Therapeutics, Inc. Inhibiting ubiquitin-specific protease 1 (usp1)
CN117136189A (zh) 2021-04-09 2023-11-28 先声再明医药有限公司 泛素特异性蛋白酶1（usp1）抑制剂
EP4430041A4 (en) 2021-11-12 2025-09-24 Insilico Medicine Ip Ltd SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) AND THEIR USES
IL312642A (en) 2021-11-12 2024-07-01 Insilico Medicine Ip Ltd Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
EP4430049A4 (en) 2021-11-12 2025-12-17 Insilico Medicine Ip Ltd Small molecule inhibitors of ubiquitin-specific protease 1 (USP1) and uses thereof
EP4605391A1 (en) 2022-10-21 2025-08-27 Exelixis, Inc. 4,5,6,7-tetrahydro-1-pyrazolo[4,3-c]pyridine compounds and derivatives as usp1 inhibitors

Also Published As

Publication number Publication date
US20240190839A1 (en) 2024-06-13
AR127646A1 (es) 2024-02-14
CO2024006269A2 (es) 2024-05-30
IL312642A (en) 2024-07-01
TW202334142A (zh) 2023-09-01
US11739077B2 (en) 2023-08-29
PE20241307A1 (es) 2024-06-24
GEAP202416532A (en) 2024-08-12
DOP2024000080A (es) 2024-11-29
EP4430050A4 (en) 2025-09-24
CL2024001397A1 (es) 2024-10-25
JP2024543477A (ja) 2024-11-21
AU2022386486A1 (en) 2024-05-09
JOP20240096A1 (ar) 2024-04-24
CR20240191A (es) 2024-09-13
EP4430050A1 (en) 2024-09-18
WO2023083286A1 (en) 2023-05-19
CN119053601A (zh) 2024-11-29
US20230183210A1 (en) 2023-06-15
MX2024005755A (es) 2024-09-06
CL2025001068A1 (es) 2025-07-11
US12570634B2 (en) 2026-03-10
US20250026754A1 (en) 2025-01-23
CA3235765A1 (en) 2023-05-19

Similar Documents

Publication Publication Date Title
KR20240117555A (ko) 유비퀴틴 특이적 프로테아제 1(usp1)의 소분자 억제제 및 이의 용도
KR20240117556A (ko) 유비퀴틴 특이적 프로테아제 1(usp1)의 소분자 억제제 및 이의 용도
KR20240101680A (ko) 유비퀴틴 특이적 프로테아제 1(usp1)의 소분자 억제제 및 이의 용도
CN111757878B (zh) 一种哒嗪类衍生物抑制剂、其制备方法和应用
WO2023114733A1 (en) Kras modulators and uses thereof
WO2022261210A1 (en) Kras modulators and uses thereof
TWI704149B (zh) 抑制瞬態電位受器ａ１離子通道
WO2025049619A1 (en) Kras modulators and uses thereof
KR101921764B1 (ko) 피라졸로-퀴놀린
CN105473576A (zh) 针对心脏病症的嘧啶二酮化合物
TW201625618A (zh) 抑制瞬時受體電位ａ１離子通道
CN117980305A (zh) 表现出mnk抑制作用的螺环吡啶-1,5-二酮及其使用方法
CN114539229A (zh) 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
JPWO2003070730A1 (ja) ピロロピリミジン誘導体
CN120530118A (zh) 一种氮杂环烷烃化合物、药物组合物及其用途
TW202334157A (zh) 一種Ｗｎｔ通路抑制劑化合物
OA21707A (en) Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof.
EA050901B1 (ru) Низкомолекулярные ингибиторы убиквитин-специфической протеазы 1 (usp1) и их применение
OA21706A (en) Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof.
OA21708A (en) Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof.
CA3235762A1 (en) Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
WO2024051795A1 (zh) 用作泛素-特异性蛋白酶抑制剂的取代嘌呤酮衍生物
CN107759522A (zh) 羧酸类衍生物、其制备方法及其在医药上的用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000